BRPI1008663A2 - fagos antibacterianos, peptídeos fágicos e métodos de utilização dos mesmos - Google Patents

fagos antibacterianos, peptídeos fágicos e métodos de utilização dos mesmos

Info

Publication number
BRPI1008663A2
BRPI1008663A2 BRPI1008663A BRPI1008663A BRPI1008663A2 BR PI1008663 A2 BRPI1008663 A2 BR PI1008663A2 BR PI1008663 A BRPI1008663 A BR PI1008663A BR PI1008663 A BRPI1008663 A BR PI1008663A BR PI1008663 A2 BRPI1008663 A2 BR PI1008663A2
Authority
BR
Brazil
Prior art keywords
methods
phage peptides
phages
antibacterial
antibacterial phages
Prior art date
Application number
BRPI1008663A
Other languages
English (en)
Inventor
Carlos Jorge Sousa De São José
Clara Isabel Rodrigues Leandro
Ferreira Llorente Grancho Lourenço
Maria Rodrigues Pardal Dias Antunes Marçal D Silva
Miguel Ângelo Da Costa Garcia
Original Assignee
Technophage Investigação E Desenvolvimento Em Biotecnologia Sa
Tecnifar Indústria Técnica Farmacêutica S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technophage Investigação E Desenvolvimento Em Biotecnologia Sa, Tecnifar Indústria Técnica Farmacêutica S A filed Critical Technophage Investigação E Desenvolvimento Em Biotecnologia Sa
Publication of BRPI1008663A2 publication Critical patent/BRPI1008663A2/pt
Publication of BRPI1008663B1 publication Critical patent/BRPI1008663B1/pt
Publication of BRPI1008663B8 publication Critical patent/BRPI1008663B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
BRPI1008663A 2009-02-06 2010-02-05 bacteriófago com um genoma, composição farmacêutica, uso de uma quantidade terapeuticamente eficaz da composição farmacêutica, método de diagnóstico do agente causador de uma infecção bacteriana e uso do bacteriófago BRPI1008663B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US15058509P 2009-02-06 2009-02-06
US61/150,585 2009-02-06
US21834509P 2009-06-18 2009-06-18
US61/218,345 2009-06-18
PCT/PT2010/000003 WO2010090542A2 (en) 2009-02-06 2010-02-05 Antibacterial phage, phage peptides and methods of use thereof

Publications (3)

Publication Number Publication Date
BRPI1008663A2 true BRPI1008663A2 (pt) 2016-03-08
BRPI1008663B1 BRPI1008663B1 (pt) 2021-01-05
BRPI1008663B8 BRPI1008663B8 (pt) 2021-10-05

Family

ID=42244489

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1008663A BRPI1008663B8 (pt) 2009-02-06 2010-02-05 bacteriófago com um genoma, composição farmacêutica, uso de uma quantidade terapeuticamente eficaz da composição farmacêutica, método de diagnóstico do agente causador de uma infecção bacteriana e uso do bacteriófago

Country Status (14)

Country Link
US (2) US9134312B2 (pt)
EP (3) EP2393502B1 (pt)
JP (3) JP5701777B2 (pt)
CN (2) CN102348460B (pt)
AU (1) AU2010211456B2 (pt)
BR (1) BRPI1008663B8 (pt)
CA (2) CA3019013C (pt)
ES (2) ES2963904T3 (pt)
HK (1) HK1166956A1 (pt)
PL (1) PL3650034T3 (pt)
PT (1) PT3115054T (pt)
RU (2) RU2580248C9 (pt)
SG (3) SG2014012611A (pt)
WO (1) WO2010090542A2 (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0607798D0 (en) * 2006-04-20 2006-05-31 Alligator Bioscience Ab Novel polypeptides and use thereof
WO2010002959A2 (en) * 2008-07-03 2010-01-07 The Rockefeller University A chimeric bacteriophage lysin with activity against staphylococci bacteria
AU2010212280B2 (en) * 2009-08-12 2015-09-24 Buddhist Tzu Chi Medical Foundation Phage of acinetobacter Baumannii
PT104837A (pt) 2009-11-24 2011-05-24 Technophage Investiga O E Desenvolvimento Em Biotecnologia S A P?ptidos de fagos enteroc?cicos e m?todos para a sua utiliza??o
CN103732235B (zh) * 2010-09-17 2018-01-02 药物技术业制药技术股份有限公司 抗菌噬菌体、噬菌体肽及其使用方法
KR101279780B1 (ko) 2011-10-05 2013-06-28 주식회사 인트론바이오테크놀로지 액티노바실러스 플루로뉴모니애에 대한 사멸능을 갖는 박테리오파지
PT2833899T (pt) 2012-03-19 2020-09-15 Technophage Investig E Desenvolvimento Em Biotecnologia Sa Composições compreendendo coquetéis de fagos e uso das mesmas para o tratamento de infeções bacterianas
WO2013164640A1 (en) * 2012-05-04 2013-11-07 Biocontrol Limited Therapeutic bacteriophage compositions
EP2865383A1 (en) * 2013-10-25 2015-04-29 Pherecydes Pharma Phage therapy of pseudomonas infections
US9029319B1 (en) * 2014-08-04 2015-05-12 Centaur, Inc. Water buffalo derived peptide antibiotic therapies
WO2016098116A1 (en) * 2014-12-17 2016-06-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Phage therapy for targeting enterococci
CN108976289B (zh) * 2015-11-20 2021-06-18 深圳市南山区人民医院 用于预防和治疗肠致病大肠杆菌感染的肽段
US20170157186A1 (en) * 2015-12-02 2017-06-08 Smart Phage, Inc. Phage to treat bacteria on skin
CN105648109B (zh) * 2016-01-08 2019-04-09 河南医学高等专科学校 一种噬菌体灭菌时化学抗菌剂筛选方法
CN106699862B (zh) * 2016-11-22 2020-06-09 中国科学院海洋研究所 三种来源于脊尾白虾alf的环状多肽及其应用和抗菌剂
DK3548053T3 (da) 2016-12-05 2022-05-09 Technophage Investig E Desenvolvimento Em Biotecnologia Sa Bakteriofagsammensætninger, der omfatter respiratoriske antibakterielle fager, og fremgangsmåder til anvendelse deraf
WO2018151867A1 (en) * 2017-02-17 2018-08-23 CAMRIS International, Inc. Universal antivenom
KR101957266B1 (ko) * 2017-02-22 2019-03-13 주식회사 인트론바이오테크놀로지 엔테로코쿠스 패슘에 대하여 용균력을 가지는 신규한 항균단백질 efal-2
CN107365363B (zh) * 2017-09-20 2020-08-04 苏州大学 小分子多肽及其应用
CN107827955B (zh) * 2017-11-21 2020-05-29 苏州大学 源于分枝杆菌噬菌体多肽的衍生肽及其应用
US20220306995A1 (en) * 2018-03-12 2022-09-29 National University Corporation Kochi University Novel bacteriophage and therapeutic agent for bacterial endophthalmitis
WO2019224941A1 (ja) * 2018-05-23 2019-11-28 国立大学法人九州大学 食中毒細菌のバクテリオファージ耐性化抑制剤及びその使用
KR102131692B1 (ko) * 2018-09-11 2020-07-08 경북대학교 산학협력단 병원성 세균을 효과적으로 사멸시키는 재조합 항균 효소 LysSAP26의 용도
RU2703043C1 (ru) * 2018-09-20 2019-10-15 Наталия Петровна Антонова Литический фермент бактериофага и антибактериальная композиция на его основе
KR102193495B1 (ko) * 2018-12-26 2020-12-22 주식회사 옵티팜 신규한 아시네토박터 바우마니 균 특이 박테리오파지 ab63 및 이를 포함하는 항균 조성물
US20220160843A1 (en) * 2019-04-05 2022-05-26 Contrafect Corporation Lysins and derivatives thereof with bactericidal activity against pseudomonas aeruginosa, in the presence of human serum
WO2020207884A1 (en) * 2019-04-09 2020-10-15 Unilever N.V. An antimicrobial composition for selective lysis of s. hominis bacteria
RU2717420C1 (ru) * 2019-06-28 2020-03-23 Акционерное общество "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Штамм бактериофага Pseudomonas aeruginosa N 327 (500321), предназначенный для приготовления моно- и поливалентных лечебно-профилактических препаратов бактериофагов
RU2717026C1 (ru) * 2019-06-28 2020-03-17 Акционерное общество "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Штамм бактериофага Pseudomonas aeruginosa N 325 (500319), предназначенный для приготовления моно- и поливалентных лечебно-профилактических препаратов бактериофагов
RU2717451C1 (ru) * 2019-06-28 2020-03-23 Акционерное общество "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Штамм бактериофага Pseudomonas aeruginosa N 323 (500317), предназначенный для приготовления моно- и поливалентных лечебно-профилактических препаратов бактериофагов
RU2717972C1 (ru) * 2019-06-28 2020-03-27 Акционерное общество "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Штамм бактериофага Pseudomonas aeruginosa N 324 (500318), предназначенный для приготовления моно- и поливалентных лечебно-профилактических препаратов бактериофагов
RU2717022C1 (ru) * 2019-06-28 2020-03-17 Акционерное общество "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Штамм бактериофага Pseudomonas aeruginosa N 328 (500322), предназначенный для приготовления моно- и поливалентных лечебно-профилактических препаратов бактериофагов
RU2717973C1 (ru) * 2019-06-28 2020-03-27 Акционерное общество "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Штамм бактериофага Pseudomonas aeruginosa N 322 (500316), предназначенный для приготовления моно- и поливалентных лечебно-профилактических препаратов бактериофагов
RU2717435C1 (ru) * 2019-06-28 2020-03-23 Акционерное общество "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Штамм бактериофага Pseudomonas aeruginosa N 326 (500320), предназначенный для приготовления моно- и поливалентных лечебно-профилактических препаратов бактериофагов
CN110499266B (zh) * 2019-08-05 2021-04-27 昆明理工大学 一株粪肠球菌及其应用
US20210187046A1 (en) 2019-12-19 2021-06-24 Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa Cocktail compositions comprising respiratory antibacterial phages and methods of use thereof
CN113214364B (zh) * 2020-01-21 2022-11-22 天津大学 一种多重耐药鲍曼不动杆菌识别元件的挖掘与验证
KR102604590B1 (ko) * 2020-09-28 2023-11-23 경북대학교 산학협력단 아시네토박터 바우마니에 대한 사멸능을 가지는 박테리오파지 및 이를 포함하는 조성물
CN116514935B (zh) * 2021-03-04 2024-04-30 西部(重庆)科学城种质创制大科学中心 RNA编辑系统的抑制剂AcrIIIA1IPLA35及其应用
WO2023113396A1 (ko) * 2021-12-14 2023-06-22 경북대학교 산학협력단 클로스트리듐 디피실 세균을 효과적으로 사멸시키는 재조합 항균 단백질의 용도
CN114703173B (zh) * 2022-03-18 2023-06-06 福建省农业科学院农业质量标准与检测技术研究所 一种λ噬菌体DNA提取试剂盒及提取方法
CN114807106B (zh) * 2022-04-25 2023-09-01 昆明市延安医院 一种裂解酶pEf51和穿孔素蛋白pEf191的应用
WO2024115430A1 (en) * 2022-11-28 2024-06-06 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Acinetobacter baumannii phages

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5863560A (en) 1996-09-11 1999-01-26 Virotex Corporation Compositions and methods for topical application of therapeutic agents
GB9712663D0 (en) * 1997-06-16 1997-08-20 Borealis As Process
US20060292135A1 (en) * 1997-10-31 2006-12-28 Lawrence Loomis Use of bacterial phage-associated lysing proteins for preventing and treating bacterial infections in humans, animals and fowl
JP2002543816A (ja) * 1999-05-13 2002-12-24 エクスポネンシャル バイオセラピーズ，アイエヌシー． バンコマイシン耐性腸球菌株に感染した患者を救済するために有用なバクテリオファージ株
EP1250143A2 (en) 2000-01-11 2002-10-23 Intralytix Inc. Reduction in bacterial colonization by administering bacteriophage compositions
RU2186574C1 (ru) * 2001-01-24 2002-08-10 Яфаев Рауэль Хасанянович Препарат поливалентного бактериофага против синегнойной палочки, штаммы бактериофага bacteriophagum pseudomonas aeruginosa спбгма им. и.и. мечникова №05, №03, №06 и №07, используемые при приготовлении поливалентного препарата против синегнойной палочки
DE60315636T2 (de) * 2002-03-25 2008-05-08 University Of Warwick, Coventry Zur therapie und prophylaxe bakterieller infektionen geeignete bakteriophagen
WO2004052274A2 (en) * 2002-12-09 2004-06-24 Phage Biopharm Llc Production of bacteriophage compositions for use in phage therapy
CN101003793A (zh) * 2007-01-11 2007-07-25 中国人民解放军第三军医大学 噬菌体对环境中致病菌的净化技术
PL215522B1 (pl) 2008-09-29 2013-12-31 Inst Immunologii I Terapii Doswiadczalnej Pan Nowe szczepy bakteriofagów do leczenia zakazen bakteryjnych, zwlaszcza szczepami bakterii lekoopornych rodzaju Enterococcus
US8563504B2 (en) * 2008-10-10 2013-10-22 Lusomedicamenta, S.A. Antibacterial phage peptides and methods of use thereof
KR20100093626A (ko) 2009-02-17 2010-08-26 서강대학교산학협력단 슈도모나스 애루지노사에 대한 파아지 치료
PT104837A (pt) 2009-11-24 2011-05-24 Technophage Investiga O E Desenvolvimento Em Biotecnologia S A P?ptidos de fagos enteroc?cicos e m?todos para a sua utiliza??o

Also Published As

Publication number Publication date
CA2751641C (en) 2018-11-13
CN105456300A (zh) 2016-04-06
RU2014127987A (ru) 2016-02-10
WO2010090542A3 (en) 2010-12-23
US20160022747A1 (en) 2016-01-28
ES2761835T3 (es) 2020-05-21
EP3115054B1 (en) 2019-11-20
JP2012517225A (ja) 2012-08-02
PT3115054T (pt) 2019-12-16
BRPI1008663B1 (pt) 2021-01-05
JP6355792B2 (ja) 2018-07-11
EP3650034A1 (en) 2020-05-13
EP3650034C0 (en) 2023-09-20
EP2393502A2 (en) 2011-12-14
JP2015154771A (ja) 2015-08-27
CN102348460B (zh) 2015-08-26
JP2017158568A (ja) 2017-09-14
PL3650034T3 (pl) 2024-03-04
CA3019013A1 (en) 2010-08-12
CN102348460A (zh) 2012-02-08
SG2014012611A (en) 2014-07-30
SG173533A1 (en) 2011-10-28
RU2580248C9 (ru) 2018-01-17
JP5701777B2 (ja) 2015-04-15
CA3019013C (en) 2020-12-15
ES2963904T3 (es) 2024-04-03
SG10201602330VA (en) 2016-04-28
BRPI1008663B8 (pt) 2021-10-05
EP2393502B1 (en) 2016-08-31
JP6177264B2 (ja) 2017-08-09
CA2751641A1 (en) 2010-08-12
RU2671110C2 (ru) 2018-10-29
CN105456300B (zh) 2019-07-09
WO2010090542A2 (en) 2010-08-12
RU2580248C2 (ru) 2016-04-10
AU2010211456B2 (en) 2016-05-26
US9682110B2 (en) 2017-06-20
EP3650034B1 (en) 2023-09-20
HK1166956A1 (zh) 2012-11-16
AU2010211456A1 (en) 2011-08-25
US20120052048A1 (en) 2012-03-01
US9134312B2 (en) 2015-09-15
RU2011134315A (ru) 2013-03-20
EP3115054A1 (en) 2017-01-11

Similar Documents

Publication Publication Date Title
BRPI1008663A2 (pt) fagos antibacterianos, peptídeos fágicos e métodos de utilização dos mesmos
PT2616087T (pt) Fagos antibacterianos, péptidos fágicos e métodos de utilização dos mesmos
DK2552434T3 (da) Peptider og anvendelse deraf
BR112012020718A2 (pt) complexo de metal-ligante e catalisador
BR112013007809A2 (pt) redireção de ambiente cruzado
BRPI1007295A8 (pt) peptídeos antibióticos
BR112013013584A2 (pt) endoscópio, e, método
BRPI1012760A2 (pt) métodos e arranjo de filtro
BR112012029028A2 (pt) laringoscópio, braços de laringoscópio e métodos de fabricação
BR112012031686A2 (pt) núcleo de válvula e válvula
EP2782589A4 (en) ANTIMICROBIAL PEPTIDES AND METHOD FOR THEIR USE
BR112012004731A2 (pt) peptídeos derivados de wnt10 e uso dos mesmos
BR112013002544A2 (pt) seção de armario e armario
DK2642992T3 (da) Forbindelser og anvendelse deraf
DK3199178T3 (da) Levende, svækket parvovirus
CL2015001689A1 (es) Parvovirus 5a porcino, métodos de uso y vacuna
BR112013014915A2 (pt) composição curativa e métodos de tratamento
BR112012021749A2 (pt) processos e compostos
BRPI1014177A2 (pt) estado de domínio, propósito e categorias
FR2962511B1 (fr) Vanne perfectionnee, et application
BRPI1010666A2 (pt) peptídeos de cdc45l e vacinas incluindo dos mesmos
BR112013015319A2 (pt) revestimento de autodeposição de aspecto brilhante aperfeiçoado, e métodos de aplicar o mesmo
ES2476366T8 (es) Procedimiento para preparar pedidos y sistema de preparación de pedidos
BRPI0923938A2 (pt) novos peptideos e uso dos mesmo
CY20142200001T2 (el) Αντιβακτηριακος παραγοντας για τη θεραπεια λοιμωδων νοσηματων βακτηριακης προελευσης

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: PAGAR RESTAURACAO.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2370 DE 07/06/2016.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/01/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/02/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2609 DE 05/01/2021 QUANTO O INVENTOR (ITEM 72)

B25A Requested transfer of rights approved

Owner name: TECHNOPHAGE, INVESTIGACAO E DESENVOLVIMENTO EM BIOTECNOLOGIA, S.A. (PT)